
Human LILRA2/CD85h/ILT1 Protein

Cat. No. LIL-HM4A2

ᠺ᠕ᡗᠴᡃ᠐ᠫ

Description	
Source	Recombinant Human LILRA2/CD85h/ILT1 Protein is expressed from HEK293 with His tag and Avi tag at the C- Terminus.
	It contains Gly24-Asn449.
Accession	Q8N149-1
Molecular Weight	The protein has a predicted MW of 49.9 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE.
Formulation and Storage	
Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background	
	LILRA2, also known as ILT1, CD85h, and LIR7, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA2 consists of a 426 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 13 aa cytoplasmic tail. LILRA2 is part of the innate immune responses against microbial infection.
Assay Data	

Bis-Tris PAGE



Human LILRA2 on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.